KLRS
Kalaris Therapeutics, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Kalaris Therapeutics (KLRS) Stock: Buy, Sell, or Hold?
$1.90
+0.03 (+1.60%)
â˛
5d:
-5.94%
30d:
-14.8%
90d:
-51.03%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (83%)
Quality Score
43/100
Position
SLIGHTLY LOW
30-Day Fair Range
$1.90 â $2.41
Position: SLIGHTLY LOW
Forward P/E & Valuation
-1.2x
Next 12M consensus est.
Wall Street Target
$18.80
+889.5% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$1.80 / $2.66
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: KLRS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When KLRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: KLRS is currently trading at $1.90, which is considered slightly low relative to its 30-day fair value range of $1.90 to $2.41.
Technical Outlook: Technically, KLRS is in a strong downtrend. Immediate support is located at $1.80, while resistance sits at $2.66.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $18.80 (+889.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KLRS is in a strong downtrend. Immediate support is located at $1.80, while resistance sits at $2.66.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $18.80 (+889.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.90 -
$2.41
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
Trading Range & Key Levels
30-Day Trading Range
$1.90 -
$2.41
Current vs Trading Range
SLIGHTLY LOW
Support Level
$1.80
Resistance Level
$2.66
Current Trend
Strong Downtrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (56/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 889.5% below Wall St target ($18.80)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-1.15
Wall Street Target
$18.80
(+889.5%)
Share KLRS Analysis
Share this live KLRS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (KLRS)
Bullish
10 Retail Mentions
StockTwits Volume
10 msgs
24h retail stream
Last Tracked
Jul 17, 2026
Daily AI digest
AI Retail Discussion Summary:
Kalaris Therapeutics reported positive results from the expanded Phase 1a SAD trial of TH103 in neovascular AMD, showing improved vision and retinal anatomy with potential for extended treatment durability.
Key Retail Themes:
Positive TH103 trial results
Potential for extended treatment durability
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 7:48 AM ET
Data refreshes hourly during market hours. Next update: 8:48 AM
Data refreshes hourly during market hours. Next update: 8:48 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KLRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 49 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$107 | 33 SELL |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
21 analysts |
$17 | 34 SELL |
|
RAPP
Rapport Therapeutics, InâĻ |
STRONG BUY
16 analysts |
$64 | 45 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive KLRS Research Pages
